Assembly Biosciences (ASMB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting commenced virtually, with recognition of outgoing chairman and introduction of board and executive attendees.
Agenda and rules of conduct were posted in the meeting portal, outlining five proposals for consideration.
Board and executive committee updates
Nine directors were nominated for election to serve until the 2027 annual meeting.
Outgoing chairman Bill Ringo was acknowledged for his leadership and contributions.
Shareholder proposals
Election of nine directors to the board.
Advisory approval of named executive officers' compensation.
Ratification of Ernst & Young LLP as independent auditor for 2026.
Amendment to the 2018 incentive plan to increase reserved shares by 1.2 million.
Amendment to the 2018 employee stock purchase plan to increase reserved shares to 515,000.
Latest events from Assembly Biosciences
- Strong clinical data and strategic partnerships set up major catalysts from 2027 to 2028.ASMB
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Key clinical milestones and expansion into new liver disease indications drive near- and long-term catalysts.ASMB
Jefferies Global Healthcare Conference 20263 Jun 2026 - Advancing oral antivirals for HSV and hepatitis D, targeting unmet needs with strong early data.ASMB
Bank of America Global Healthcare Conference 202614 May 2026 - Long-acting antivirals for herpes and hepatitis advance with strong efficacy, safety, and Gilead partnership.ASMB
Corporate presentation8 May 2026 - Gilead exercised its HPI option, $35M paid, $9.1M net loss, and strong cash reserves maintained.ASMB
Q1 20267 May 2026 - Board recommends approval of all proposals, including director elections and plan amendments.ASMB
Proxy filing23 Apr 2026 - Board recommends approval of all annual meeting proposals, including equity plan amendments.ASMB
Proxy filing23 Apr 2026 - Biotech firm launches $100M at-the-market stock offering to fund antiviral pipeline and operations.ASMB
Registration filing19 Mar 2026 - 2025 revenue jumped to $72.3M, net loss shrank to $6.1M, and cash reserves rose to $248.1M.ASMB
Q4 202519 Mar 2026